- 21 November 2019
1:00 pm - 2:00 pm
THURSDAY 21 November 2019, 1.00 PM
Auditorium, Level 6, Bancroft Building
Function and Clinical Utility of Cancer-derived Exosomes
Associate Professor Andreas Möller
Tumour Microenvironment Laboratory
QIMR Berghofer Medical Research Institute
Late diagnosis and lack of reliable prognostic outcome predictions are important clinically unmet needs. Reasons for our inability to generate reliable diagnostic, prognostic and/or predictive biomarkers are the incomplete understanding of cancer progression, especially metastatic spread. For a cancer to spread from the primary site to distant organs, a large number of essential steps have to be overcome. We, and others, showed that cancer-secreted factors, including extracellular vesicles (EVs), are mediators of creating immune-suppressed, permissive environments (pre-metastatic niches) at distant organs before the arrival of cancer cells.In this presentation, I will summarize the research approaches in cancer-derived EVs, especially exosomes, undertaken by my group. I will discuss novel data on how cancer-derived exosomes can specifically distribute to certain organs in the body, depending on the tumour microenvironment of the primary tumours. These modifications increase pre-metastatic niche formation and metastatic spread. Analysing the content of cancer-derived exosomes, I will additionally show intriguing clinical data on how the content of plasma exosomes can be used to diagnose cancer in the first place and then to predict the outcome of a patient at baseline.
Dr. Andreas Möller is Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. He joined the QIMR Berghofer in November 2012 after being Peter Mac Research Fellow at the Peter MacCallum Cancer Centre, Melbourne. He conducted his doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg and subsequently undertook Postdoctoral training at the University of Berne, Switzerland. His current, innovative multidisciplinary research approach combines the fields of cancer immunology, cancer biology, nanotechnology and metastasis.